Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer

Oncology Letters

Volumn 5, Issue 4, 2013, Pages 1315-1320

  Ying, Lisha ^a   Su, Dan ^a   Zhu, Jianqing ^a   Ma, Shenglin ^a   Katsaros, Dionyssios ^b   Yu, Herbert ^c  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Genetic polymorphisms; Genotype; Haplotype; Ovarian cancer; Stathmin

Indexed keywords

PACLITAXEL; PLATINUM; STATHMIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DISEASE COURSE; FEMALE; GENE; GENE EXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PHENOTYPE; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATHMIN GENE; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84874400344     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1144     Document Type: Article

References (37)

1. Du Bois A, Lück HJ, Meier W, et al: Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie. Semin Oncol 24 (4 Suppl 11): S11-28-S11-33, 1997.
2. Aravantinos G, Fountzilas G, Kosmidis P, et al: Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 16: 1116-1122, 2005.
3. Buttmann M, Nowak E, Kroner A, Hemmer B, Lesch KP and Rieckmann P: Analysis of the stathmin rs182455 single nucleotide promoter polymorphism in patients with multiple sclerosis. J Neurogenet 22: 181-186, 2008.
4. Lippert TH, Ruoff H and Volm M: Intrinsic and Acquired Drug Resistance in Malignant Tumors. The main reason for therapeutic failure. Arzneimittelforschung 58: 261-264, 2008.
5. Fleming ND, Agadjanian H, Nassanian H, et al: Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer 118: 689-697, 2012.
6. Lose F, Nagle CM, O'Mara T, et al: Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecol Oncol 119: 479-483, 2010.
7. Quaye L, Gayther SA, Ramus SJ, et al: The effects of common genetic variants in oncogenes on ovarian cancer survival. Clin Cancer Res 14: 5833-5839, 2008.
8. Belmont LD and Mitchison TJ: Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 84: 623-631, 1996.
9. Golouh R, Cufer T, Sadikov A, et al: The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 110: 317-326, 2008.
10. Zheng P, Liu YX, Chen L, et al: Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res 9: 4897-4905, 2010.
11. Trovik J, Wik E, Stefansson IM, et al: Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 17: 3368-3377, 2011.
12. Canzonieri V, Barzan L, Franchin G, et al: Alteration of G1/S transition regulators influences recurrences in head and neck squamous carcinomas. J Cell Physiol 227: 233-238, 2012.
13. Singer S, Ehemann V, Brauckhoff A, et al: Protumorigenic over-expression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology 46: 759-768, 2007.
14. Rosell R, Scagliotti G, Danenberg KD, et al: Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548-3553, 2003.
15. Wei SH, Lin F, Wang X, Gao P and Zhang HZ: Prognostic significance of stathmin expression in correlation with metastasis and clinicopathological characteristics in human ovarian carcinoma. Acta Histochem 110: 59-65, 2008.
16. Ghosh R, Gu G, Tillman E, et al: Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate 67: 1038-1052, 2007.
17. Carr JR, Park HJ, Wang Z, Kiefer MM and Raychaudhuri P: FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70: 5054-5063, 2010.
18. Alli E, Yang JM and Hait WN: Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 26: 1003-1012, 2007.
19. Su D, Smith SM, Preti M, et al: Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 115: 2453-2463, 2009.
20. Shepherd JH: Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 96: 889-892, 1989.
21. Scully RE and Sobin LH: Histologic typing of ovarian tumors. Arch Pathol Lab Med 111: 794-795, 1987.
22. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
23. Rustin GJ, Nelstrop AE, Tuxen MK and Lambert HE: Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7: 361-364, 1996.
24. Sobel A and Tashjian AH Jr: Distinct patterns of cytoplasmic protein phosphorylation related to regulation of synthesis and release of prolactin by GH cells. J Biol Chem 258: 10312-10324, 1983.
25. Belletti B and Baldassarre G: Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Target 15: 1249-1266, 2011.
26. Saunders MA, Liang H and Li WH: Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA 104: 3300-3305, 2007.
27. Sun G, Yan J, Noltner K, et al: SNPs in human miRNA genes affect biogenesis and function. RNA 15: 1640-1651, 2009.
28. Pagani F and Baralle FE: Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 5: 389-396, 2004.
29. Jourdain I, Lachkar S, Charbaut E, et al: A synergistic relationship between three regions of stathmin family proteins is required for the formation of a stable complex with tubulin. Biochem J 378: 877-888, 2004.
30. Jourdain L, Curmi P, Sobel A, Pantaloni D and Carlier MF: Stathmin: a tubulin-sequestering protein which forms a ternary T2S complex with two tubulin molecules. Biochemistry 36: 10817-10821, 1997.
31. Oishi Y, Nagasaki K, Miyata S, et al: Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer. J Hum Genet 52: 271-279, 2007.
32. Salvesen HB, Carter SL, Mannelqvist M, et al: Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 106: 4834-4839, 2009.
33. Yuan RH, Jeng YM, Chen HL, et al: Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209: 549-558, 2006.
34. Meng XL, Su D, Wang L, et al: Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxel-containing regimens in locally advanced breast cancer. Genet Test Mol Biomarkers 16: 689-694, 2012.
35. Brocke B, Lesch KP, Armbruster D, et al: Stathmin, a gene regulating neural plasticity, affects fear and anxiety processing in humans. Am J Med Genet B Neuropsychiatr Genet 153B: 243-251, 2010.
36. Ehlis AC, Bauernschmitt K, Dresler T, et al: Influence of a genetic variant of the neuronal growth associated protein Stathmin 1 on cognitive and affective control processes: an event-related potential study. Am J Med Genet B Neuropsychiatr Genet 156B: 291-302, 2011.
37. Yamada K, Matsuzaki S, Hattori T, et al: Increased stathmin1 expression in the dentate gyrus of mice causes abnormal axonal arborizations. PLoS One 5: e8596, 2010.